Clinical Application of Three-Dimensional Esophageal Computed Tomography Combined with Serum β-hCG in Diagnosis of Esophageal Cancer

Abstract

Background: This study is undertaken to explore the diagnostic value of three-dimensional esophageal computed tomography (CT) combined with human chorionic gonadotropin β subunit (β-hCG) in esophageal cancer. Methods: The clinical data of 76 patients with suspected esophageal cancer admitted to our hospital from August 2022 to February 2023 were retrospectively analyzed. According to the pathological diagnosis results of gastroscopic biopsy, 49 patients with esophageal cancer were assigned to the esophageal cancer group and 27 patients with benign cancer were assigned to the benign group. Three-dimensional esophageal CT and serum β-hCG examination were performed in all patients. The results of serum β-hCG level detection and three-dimensional esophageal CT examination were collected and compared with the pathological diagnosis results of gastroscopy biopsy. The diagnostic value of three-dimensional esophageal CT combined with serum β-hCG was analyzed by receiver operating characteristic (ROC) curve area (AUC). Results: The serum β-hCG level in esophageal carcinoma group was significantly higher than that in benign group (p < 0.05). The accuracy of three-dimensional esophageal CT and serum β-hCG in the diagnosis of esophageal cancer was 92.11% and 81.58%, respectively. The AUC of three-dimensional esophageal CT, β-hCG, and their joint detection in the diagnosis of esophageal cancer was 0.922, 0.914, and 0.958, respectively. Conclusion: Three-dimensional esophageal CT combined with serum β-hCG may have a better diagnostic value in esophageal cancer.